NCT00936819.

Trial name or title	The enhanced angiogenic cell therapy ‐ acute myocardial infarction trial (ENACT‐AMI)
Methods	Type of study: parallel RCT Source of funding: not reported Country of origin: Canada Number of centres: 5 Intended enrolment: 100
Participants	Population: AMI Age, mean (SD) each arm: not reported (18 to 80 years) Sex, % male in each arm: not reported Number of diseased vessels: not reported Number of stunned hyperkinetic, etc segments: not reported Time from symptom onset to initial treatment: not reported Statistically significant baseline imbalances between the groups?: not reported
Interventions	Intervention arm: endothelial progenitor cells (EPC) or eNOS transfected EPC Type of stem cells: endothelial progenitor cells (EPC) Summary of how stem cells were isolated and type and route of delivery: not reported Dose of stem cells: 20 x 106 cells in each treatment arm Timing of stem cell procedure: after 5 to 7 days Comparator arm: plasmalyte and 25% autologous plasma
Outcomes	Primary outcome: change in LVEF Secondary outcomes: changes in wall motion, clinical worsening, QoL and safety Outcome assessment points: baseline and 6 months Method(s): MRI
Starting date	July 2013
Contact information	Contact: Dr. Duncan J. Stewart, MD FRCP C, Ottawa Hospital Research Institute
Notes	—